- Randomized controlled trial
A randomized controlled trial (RCT) is a type of scientific experiment - a form of clinical trial - most commonly used in testing the safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy or effectiveness of healthcare services (such as medicine or nursing) or health technologies (such as pharmaceuticals, medical devices or surgery). The key distinguishing feature of the usual RCT is that study subjects, after assessment of eligibility and recruitment, but before the intervention to be studied begins, are randomly allocated to receive one or other of the alternative treatments under study. Random allocation in real trials is complex, but conceptually, the process is like tossing a coin. After randomization, the two (or more) groups of subjects are followed up in exactly the same way, and the only differences between the care they receive, for example, in terms of procedures, tests, outpatient visits, follow-up calls etc. should be those intrinsic to the treatments being compared. The most important advantage of proper randomization is that it minimises allocation bias, balancing both known and unknown prognostic factors, in the assignment of treatments."
The terms "RCT" and randomized trial are often used synonymously, but some authors distinguish between "RCTs" which compare treatment groups with control groups not receiving treatment (as in a placebo-controlled study), and "randomized trials" which can compare multiple treatment groups with each other. RCTs are sometimes known as randomized control trials. RCTs are also called randomized clinical trials or randomized controlled clinical trials when they concern clinical research; however, RCTs are also employed in other research areas such as criminology, education, social work and international development.
Randomized experiments first appeared in psychology, where they were introduced by Charles Sanders Peirce, and in education. Later, randomized experiments appeared in agriculture, due to Jerzy Neyman and Ronald A. Fisher. Fisher's experimental research and his writings popularized randomized experiments.
The first published RCT appeared in the 1948 paper entitled "Streptomycin treatment of pulmonary tuberculosis", which described a Medical Research Council investigation. One of the authors of that paper was Austin Bradford Hill, who is credited as having conceived the modern RCT.
By the late 20th century, RCTs were recognized as the standard method for "rational therapeutics" in medicine. As of 2004, more than 150,000 RCTs were in the Cochrane Library. To improve the reporting of RCTs in the medical literature, an international group of scientists and editors published Consolidated Standards of Reporting Trials (CONSORT) Statements in 1996, 2001, and 2010 which have become widely accepted.
Although the principle of clinical equipoise ("genuine uncertainty within the expert medical community... about the preferred treatment") common to clinical trials has been applied to RCTs, the ethics of RCTs have special considerations. For one, it has been argued that equipoise itself is insufficient to justify RCTs. For another, "collective equipoise" can conflict with a lack of personal equipoise (e.g., a personal belief that an intervention is effective). Finally, Zelen's design, which has been used for some RCTs, randomizes subjects before they provide informed consent, which may be ethical for RCTs of screening and selected therapies, but is likely unethical "for most therapeutic trials."
Classifications of RCTs
By study design
- Parallel-group – each participant is randomly assigned to a group, and all the participants in the group receive (or do not receive) an intervention.
- Crossover – over time, each participant receives (or does not receive) an intervention in a random sequence.
- Split-body – separate parts of the body of each participant (e.g., the left and right sides of the face) are randomized to receive (or not receive) an intervention.
- Cluster – pre-existing groups of participants (e.g., villages, schools) are randomly selected to receive (or not receive) an intervention.
- Factorial – each participant is randomly assigned to a group that receives a particular combination of interventions or non-interventions (e.g., group 1 receives vitamin X and vitamin Y, group 2 receives vitamin X and placebo Y, group 3 receives placebo X and vitamin Y, and group 4 receives placebo X and placebo Y).
By outcome of interest (efficacy vs. effectiveness)
RCTs can be classified as "explanatory" or "pragmatic." Explanatory RCTs test efficacy in a research setting with highly selected participants and under highly controlled conditions. In contrast, pragmatic RCTs test effectiveness in everyday practice with relatively unselected participants and under flexible conditions; in this way, pragmatic RCTs can "inform decisions about practice."
By hypothesis (superiority vs. noninferiority vs. equivalence)
Another classification of RCTs categorizes them as "superiority trials," "noninferiority trials," and "equivalence trials," which differ in methodology and reporting. Most RCTs are superiority trials, in which one intervention is hypothesized to be superior to another in a statistically significant way. Some RCTs are noninferiority trials "to determine whether a new treatment is no worse than a reference treatment." Other RCTs are equivalence trials in which the hypothesis is that two interventions are indistinguishable from each other.
- "It eliminates bias in treatment assignment," specifically selection bias and confounding.
- "It facilitates blinding (masking) of the identity of treatments from investigators, participants, and assessors."
- "It permits the use of probability theory to express the likelihood that any difference in outcome between treatment groups merely indicates chance."
There are two processes involved in randomizing patients to different interventions. First is choosing a randomization procedure to generate an unpredictable sequence of allocations; this may be a simple random assignment of patients to any of the groups at equal probabilities, may be "restricted," or may be "adaptive." A second and more practical issue is allocation concealment, which refers to the stringent precautions taken to ensure that the group assignment of patients are not revealed prior to definitively allocating them to their respective groups. Non-random "systematic" methods of group assignment, such as alternating subjects between one group and the other, can cause "limitless contamination possibilities" and can cause a breach of allocation concealment.
An ideal randomization procedure would achieve the following goals:
- Equal group sizes for adequate statistical power, especially in subgroup analyses.
- Low selection bias. That is, the procedure should not allow an investigator to predict the next subject's group assignment by examining which group has been assigned the fewest subjects up to that point.
- Low probability of confounding (i.e., a low probability of "accidental bias"), which implies a balance in covariates across groups. If the randomization procedure causes an imbalance in covariates related to the outcome across groups, estimates of effect may be biased if not adjusted for the covariates (which may be unmeasured and therefore impossible to adjust for).
However, no single randomization procedure meets those goals in every circumstance, so researchers must select a procedure for a given study based on its advantages and disadvantages.
This is a commonly used and intuitive procedure, similar to "repeated fair coin-tossing." Also known as "complete" or "unrestricted" randomization, it is robust against both selection and accidental biases. However, its main drawback is the possibility of imbalanced group sizes in small RCTs. It is therefore recommended only for RCTs with over 200 subjects.
- Permuted-block randomization or blocked randomization: a "block size" and "allocation ratio" (number of subjects in one group versus the other group) are specified, and subjects are allocated randomly within each block. For example, a block size of 6 and an allocation ratio of 2:1 would lead to random assignment of 4 subjects to one group and 2 to the other. This type of randomization can be combined with "stratified randomization", for example by center in a multicenter trial, to "ensure good balance of participant characteristics in each group." A special case of permuted-block randomization is random allocation, in which the entire sample is treated as one block. The major disadvantage of permuted-block randomization is that even if the block sizes are large and randomly varied, the procedure can lead to selection bias. Another disadvantage is that "proper" analysis of data from permuted-block-randomized RCTs requires stratification by blocks.
- Adaptive biased-coin randomization methods (of which urn randomization is the most widely-known type): In these relatively uncommon methods, the probability of being assigned to a group decreases if the group is over-represented and increases if the group is under-represented. The methods are thought to be less affected by selection bias than permuted-block randomization.
At least two types of "adaptive" randomization procedures have been used in RCTs, but much less frequently than simple or restricted randomization:
- Covariate-adaptive randomization, of which one type is minimization: The probability of being assigned to a group varies in order to minimize "covariate imbalance." Minimization is reported to have "supporters and detractors"; because only the first subject's group assignment is truly chosen at random, the method does not necessarily eliminate bias on unknown factors.
- Response-adaptive randomization, also known as outcome-adaptive randomization: The probability of being assigned to a group increases if the responses of the prior patients in the group were favorable. Although arguments have been made that this approach is more ethical than other types of randomization when the probability that a treatment is effective or ineffective increases during the course of an RCT, ethicists have not yet studied the approach in detail.
"Allocation concealment" (defined as "the procedure for protecting the randomisation process so that the treatment to be allocated is not known before the patient is entered into the study") is considered desirable in RCTs. In practice, in taking care of individual patients, clinical investigators in RCTs often find it difficult to maintain impartiality. Stories abound of investigators holding up sealed envelopes to lights or ransacking offices to determine group assignments in order to dictate the assignment of their next patient. Such practices introduce selection bias and confounders (both of which should be minimized by randomization), thereby possibly distorting the results of the study. Adequate allocation concealment should defeat patients and investigators from discovering treatment allocation once a study is underway and after the study has concluded. Treatment related side-effects or adverse events may be specific enough to reveal allocation to investigators or patients thereby introducing bias or influencing any subjective parameters collected by investigators or requested from subjects.
Some standard methods of ensuring allocation concealment include sequentially-numbered, opaque, sealed envelopes (SNOSE); sequentially-numbered containers; pharmacy controlled randomization; and central randomization. It is recommended that allocation concealment methods be included in an RCT's protocol, and that the allocation concealment methods should be reported in detail in a publication of an RCT's results; however, 2005 study determined that most RCTs have unclear allocation concealment in their protocols, in their publications, or both. On the other hand, a 2008 study of 146 meta-analyses concluded that the results of RCTs with inadequate or unclear allocation concealment tended to be biased toward beneficial effects only if the RCTs' outcomes were subjective as opposed to objective.
An RCT may be Blinded, (also called "masked") by "procedures that prevent study participants, caregivers, or outcome assessors from knowing which intervention was received." Unlike allocation concealment, blinding is sometimes inappropriate or impossible to perform in an RCT; for example, if an RCT involves a treatment in which active participation of the patient is necessary (e.g., physical therapy), participants cannot be blinded to the intervention.
Traditionally, blinded RCTs have been classified as "single-blind," "double-blind," or "triple-blind"; however, in 2001 and 2006 two studies showed that these terms have different meanings for different people. The 2010 CONSORT Statement specifies that authors and editors should not use the terms "single-blind," "double-blind," and "triple-blind"; instead, reports of blinded RCT should discuss "If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how."
RCTs without blinding are referred to as "unblinded", "open", or (if the intervention is a medication) "open-label". In 2008 a study concluded that the results of unblinded RCTs tended to be biased toward beneficial effects only if the RCTs' outcomes were subjective as opposed to objective; for example, in an RCT of treatments for multiple sclerosis, unblinded neurologists (but not blinded neurologists) felt that the treatments were beneficial. In pragmatic RCTs, although the participants and providers are often unblinded, it is "still desirable and often possible to blind the assessor or obtain an objective source of data for evaluation of outcomes."
Analysis of data from RCTs
The types of statistical methods used in RCTs depend on the characteristics of the data and include:
- For dichotomous (binary) outcome data, logistic regression (e.g., to predict sustained virological response after receipt of peginterferon alfa-2a for hepatitis C) and other methods can be used.
- For continuous outcome data, analysis of covariance (e.g., for changes in blood lipid levels after receipt of atorvastatin after acute coronary syndrome) tests the effects of predictor variables.
- For time-to-event outcome data that may be censored, survival analysis (e.g., Kaplan–Meier estimators and Cox proportional hazards models for time to coronary heart disease after receipt of hormone replacement therapy in menopause) is appropriate.
Regardless of the statistical methods used, important considerations in the analysis of RCT data include:
- Whether a RCT should be stopped early due to interim results. For example, RCTs may be stopped early if an intervention produces "larger than expected benefit or harm," or if "investigators find evidence of no important difference between experimental and control interventions."
- The extent to which the groups can be analyzed exactly as they existed upon randomization (i.e., whether a so-called "intention-to-treat analysis" is used). A "pure" intention-to-treat analysis is "possible only when complete outcome data are available" for all randomized subjects; when some outcome data are missing, options include analyzing only cases with known outcomes and using imputed data. Nevertheless, the more that analyses can include all participants in the groups to which they were randomized, the less bias that an RCT will be subject to.
- Whether subgroup analysis should be performed. These are "often discouraged" because multiple comparisons may produce false positive findings that cannot be confirmed by other studies.
Reporting of RCT results
The CONSORT 2010 Statement is "an evidence-based, minimum set of recommendations for reporting RCTs." The CONSORT 2010 checklist contains 25 items (many with sub-items) focusing on "individually randomised, two group, parallel trials" which are the most common type of RCT. For other RCT study designs, "CONSORT extensions" have been published.
RCTs are considered by most to be the most reliable form of scientific evidence in the hierarchy of evidence that influences healthcare policy and practice because RCTs reduce spurious causality and bias. Results of RCTs may be combined in systematic reviews which are increasingly being used in the conduct of evidence-based medicine. Some examples of scientific organizations' considering RCTs or systematic reviews of RCTs to be the highest-quality evidence available are:
- As of 1998, the National Health and Medical Research Council of Australia designated "Level I" evidence as that "obtained from a systematic review of all relevant randomised controlled trials" and "Level II" evidence as that "obtained from at least one properly designed randomised controlled trial."
- Since at least 2001, in making clinical practice guideline recommendations the United States Preventive Services Task Force has considered both a study's design and its internal validity as indicators of its quality. It has recognized "evidence obtained from at least one properly randomized controlled trial" with good internal validity (i.e., a rating of "I-good") as the highest quality evidence available to it.
- The GRADE Working Group concluded in 2008 that "randomised trials without important limitations constitute high quality evidence."
- For issues involving "Therapy/Prevention, Aetiology/Harm," the Oxford Centre for Evidence-based Medicine]] as of 2009 defined "Level 1a" evidence as a systematic review of RCTs that are consistent with each other, and "Level 1b" evidence as an "individual RCT (with narrow Confidence Interval)."
Notable RCTs with unexpected results that contributed to changes in clinical practice include:
- After Food and Drug Administration approval, the antiarrhythmic agents flecainide and encainide came to market in 1986 and 1987 respectively. The non-randomized studies concerning the drugs were characterized as "glowing", and their sales increased to a combined total of approximately 165,000 prescriptions per month in early 1989. In that year, however, a preliminary report of a RCT concluded that the two drugs increased mortality. Sales of the drugs then decreased.
- Prior to 2002, based on observational studies, it was routine for physicians to prescribe hormone replacement therapy for post-menopausal women to prevent myocardial infarction. In 2002 and 2004, however, published RCTs from the Women's Health Initiative claimed that women taking hormone replacement therapy with estrogen plus progestin had a higher rate of myocardial infarctions than women on a placebo, and that estrogen-only hormone replacement therapy caused no reduction in the incidence of coronary heart disease. Possible explanations for the discrepancy between the observational studies and the RCTs involved differences in methodology, in the hormone regimens used, and in the populations studied. The use of hormone replacement therapy decreased after publication of the RCTs.
Limitations of external validity
- Where the RCT was performed (e.g., what works in one country may not work in another)
- Characteristics of the patients (e.g., an RCT may include patients whose prognosis is better than average, or may exclude "women, children, the elderly, and those with common medical conditions")
- Study procedures (e.g., in an RCT patients may receive intensive diagnostic procedures and follow-up care difficult to achieve in the "real world")
- Outcome measures (e.g., RCTs may use composite measures infrequently used in clinical practice)
- Incomplete reporting of adverse effects of interventions
RCTs can be expensive; one study found 28 Phase III RCTs funded by the National Institute of Neurological Disorders and Stroke prior to 2000 with a total cost of US$335 million, for a mean cost of US$12 million per RCT. Nevertheless, the return on investment of RCTs may be high, in that the same study projected that the 28 RCTs produced a "net benefit to society at 10-years" of 46 times the cost of the trials program, based on evaluating a quality-adjusted life year as equal to the prevailing mean per capita gross domestic product.
The conduction of a RCT takes several years until being published, thus data is restricted from the medical community for long years and may be of less relevance at time of publication.
Relative importance of RCTs and observational studies
Two studies published in The New England Journal of Medicine in 2000 found that observational studies and RCTs overall produced similar results. The authors of the 2000 findings cast doubt on the ideas that "observational studies should not be used for defining evidence-based medical care" and that RCTs' results are "evidence of the highest grade." However, a 2001 study published in Journal of the American Medical Association concluded that "discrepancies beyond chance do occur and differences in estimated magnitude of treatment effect are very common" between observational studies and RCTs.
Two other lines of reasoning question RCTs' contribution to scientific knowledge beyond other types of studies:
- If study designs are ranked by their potential for new discoveries, then anecdotal evidence would be at the top of the list, followed by observational studies, followed by RCTs.
- RCTs may be unnecessary for treatments that have dramatic and rapid effects relative to the expected stable or progressively worse natural course of the condition treated. One example is combination chemotherapy including cisplatin for metastatic testicular cancer, which increased the cure rate from 5% to 60% in a 1977 non-randomized study.
Difficulty in studying rare events
Interventions to prevent events that occur only infrequently (e.g., sudden infant death syndrome) and uncommon adverse outcomes (e.g., a rare side effect of a drug) would require RCTs with extremely large sample sizes and may therefore best be assessed by observational studies.
Difficulty in studying outcomes in distant future
Pro-industry findings in industry-funded RCTs
Some RCTs are fully or partly funded by the health care industry (e.g., the pharmaceutical industry) as opposed to government, nonprofit, or other sources. A systematic review published in 2003 found four 1986-2002 articles comparing industry-sponsored and nonindustry-sponsored RCTs, and in all the articles there was a correlation of industry sponsorship and positive study outcome. A 2004 study of 1999-2001 RCTs published in leading medical and surgical journals determined that industry-funded RCTs "are more likely to be associated with statistically significant pro-industry findings." One possible reason for the pro-industry results in industry-funded published RCTs is publication bias.
Although subjects almost always provide informed consent for their participation in an RCT, studies since 1982 have documented that many RCT subjects believe that they are certain to receive treatment that is best for them personally; that is, they do not understand the difference between research and treatment. Further research is necessary to determine the prevalence of and ways to address this "therapeutic misconception".
Narrowing of the studied question
Randomized clinical trials are usually only inspect one variable or very few variables, rarely reflecting the full picture of a complicated medical situation; whereas the case report, for example, can detail many different aspects of the patient’s medical situation (e.g. patient history, physical examination, diagnosis, psychosocial aspects, follow up).
RCTs are subject to both type I ("false positive") and type II ("false negative") statistical errors. Regarding Type I errors, a typical RCT will use 0.05 (i.e., 1 in 20) as the probability that the RCT will falsely find two equally effective treatments significantly different. Regarding Type II errors, despite the publication of a 1978 paper noting that the sample sizes of many "negative" RCTs were too small to make definitive conclusions about the negative results, by 2005-2006 a sizeable proportion of RCTs still had inaccurate or incompletely-reported sample size calculations.
The RCT method creates cultural effects that have not been well understood. For example, patients with terminal illness may attempt to join trials as a last ditch attempt at treatment, even when treatments are unlikely to be successful.
Conflict of interest dangers
A 2011 study done to disclose possible conflicts of interests in underlying research studies used for medical meta-analyses reviewed 29 meta-analyses and found that conflicts of interests in the studies underlying the meta-analyses were rarely disclosed. The 29 meta-analyses included 11 from general medicine journals; 15 from specialty medicine journals, and 3 from the Cochrane Database of Systematic Reviews. The 29 meta-analyses reviewed an aggregate of 509 randomized controlled trials (RCTs). Of these, 318 RCTs reported funding sources with 219 (69%) industry funded. 132 of the 509 RCTs reported author conflict of interest disclosures, with 91 studies (69%) disclosing industry financial ties with one or more authors. The information was, however, seldom reflected in the meta-analyses. Only two (7%) reported RCT funding sources and none reported RCT author-industry ties. The authors concluded “without acknowledgment of COI due to industry funding or author industry financial ties from RCTs included in meta-analyses, readers’ understanding and appraisal of the evidence from the meta-analysis may be compromised.”
RCTs in criminology, education, and international development
A 2005 review found 83 randomized experiments in criminology published in 1982-2004, compared with only 35 published in 1957-1981. The authors classified the studies they found into five categories: "policing", "prevention", "corrections", "court", and "community". Focusing only on offending behavior programs, Hollin (2008) argued that RCTs may be difficult to implement (e.g., if an RCT required "passing sentences that would randomly assign offenders to programmes") and therefore that experiments with quasi-experimental design are still necessary.
RCTs have been used in evaluating a number of educational interventions. For example, a 2009 study randomized 260 elementary school teachers' classrooms to receive or not receive a program of behavioral screening, classroom intervention, and parent training, and then measured the behavioral and academic performance of their students. Another 2009 study randomized classrooms for 678 first-grade children to receive a classroom-centered intervention, a parent-centered intervention, or no intervention, and then followed their academic outcomes through age 19.
RCTs are currently being used by a number of international development experts to measure the impact of development interventions worldwide. Development economists at research organizations including Abdul Latif Jameel Poverty Action Lab and Innovations for Poverty Action have used RCTs to measure the effectiveness of poverty, health, and education programs in the developing world. While RCTs can be useful in policy evaluation, it is necessary to exercise care in interpreting the results in social science settings. For example, interventions can inadvertently induce socioeconomic and behavioral changes that can confound the relationships (Bhargava, 2008).
For some development economists, the main benefit to using RCTs compared to other research methods is that randomization guards against selection bias, a problem present in many current studies of development policy. In one notable example of a cluster RCT in the field of development economics, Olken (2007) randomized 608 villages in Indonesia in which roads were about to be built into six groups (no audit vs. audit, and no invitations to accountability meetings vs. invitations to accountability meetings vs. invitations to accountability meetings along with anonymous comment forms). After estimating "missing expenditures" (a measure of corruption), Olken concluded that government audits were more effective than "increasing grassroots participation in monitoring" in reducing corruption. However, similar conclusions can also be reached by suitable modeling of the data from longitudinal studies. Overall, it is important in social sciences to account for the intended as well as the unintended consequences of interventions for policy evaluations.
- ^ a b c d Schulz KF, Altman DG, Moher D; for the CONSORT Group (2010). "CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials". Br Med J 340: c332. doi:10.1136/bmj.c332. PMC 2844940. PMID 20332509. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2844940.
- ^ a b c d e f g h i Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010). "CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials". Br Med J 340: c869. doi:10.1136/bmj.c869. PMC 2844943. PMID 20332511. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2844943.
- ^ Ranjith G (2005). "Interferon-α-induced depression: when a randomized trial is not a randomized controlled trial". Psychother Psychosom 74 (6): 387. doi:10.1159/000087787. PMID 16244516.
- ^ Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A (1981). "A method for assessing the quality of a randomized control trial". Control Clin Trials 2 (1): 31–49. doi:10.1016/0197-2456(81)90056-8. PMID 7261638.
- ^ Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1976). "Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design". Br J Cancer 34 (6): 585–612. doi:10.1038/bjc.1976.220. PMC 2025229/. PMID 795448. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2025229/.
- ^ Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977). "Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples". Br J Cancer 35 (1): 1–39. doi:10.1038/bjc.1977.1. PMC 2025310. PMID 831755. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2025310.
- ^ Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H (2004). "Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial". Lancet 364 (9429): 141–8. doi:10.1016/S0140-6736(04)16626-9. PMID 15246726.
- ^ Charles Sanders Peirce and Joseph Jastrow (1885). "On Small Differences in Sensation". Memoirs of the National Academy of Sciences 3: 73–83. http://psychclassics.yorku.ca/Peirce/small-diffs.htm. http://psychclassics.yorku.ca/Peirce/small-diffs.htm
- ^ Hacking, Ian (September 1988). "Telepathy: Origins of Randomization in Experimental Design". Isis 79 (3): 427–451. doi:10.1086/354775. JSTOR 234674. MR1013489.
- ^ Stephen M. Stigler (November 1992). "A Historical View of Statistical Concepts in Psychology and Educational Research". American Journal of Education 101 (1): 60–70. doi:10.1086/444032.
- ^ Trudy Dehue (December 1997). "Deception, Efficiency, and Random Groups: Psychology and the Gradual Origination of the Random Group Design". Isis 88 (4): 653–673. doi:10.1086/383850. PMID 9519574.
- ^ Neyman, Jerzy. 1923 . “On the Application of Probability Theory to AgriculturalExperiments. Essay on Principles. Section 9.” Statistical Science 5 (4): 465–472. Trans. Dorota M. Dabrowska and Terence P. Speed.
- ^ According to Conniffe (1991, p. 87),
Ronald A. Fisher was "interested in application and in the popularization of statistical methods and his early book Statistical Methods for Research Workers, published in 1925, went through many editions and motivated and influenced the practical use of statistics in many fields of study. His Design of Experiments (1935) [promoted] statistical technique and application. In that book he emphasized examples and how to design experiments systematically from a statistical point of view. The mathematical justification of the methods described was not stressed and, indeed, proofs were often barely sketched or omitted altogether ..., a fact which led H. B. Mann to fill the gaps with a rigorous mathematical treatment in his well known treatise, Mann (1949)."
Page 87: Conniffe, Denis (1990–1991). "R. A. Fisher and the development of statistics—a view in his centenary year". Journal of the Statistical and Social Inquiry Society of Ireland (Dublin: Statistical and Social Inquiry Society of Ireland) XXVI (3): pp. 55–108. ISSN 0081-4776. http://www.tara.tcd.ie/jspui/handle/2262/2764.
- ^ Streptomycin in Tuberculosis Trials Committee (1948). "Streptomycin treatment of pulmonary tuberculosis. A Medical Research Council investigation". Br Med J 2 (4582): 769–82. doi:10.1136/bmj.2.4582.769. PMC 2091872. PMID 18890300. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2091872.
- ^ Brown D (1998-11-02). "Landmark study made research resistant to bias". Washington Post.
- ^ Shikata S, Nakayama T, Noguchi Y, Taji Y, Yamagishi H (2006). "Comparison of effects in randomized controlled trials with observational studies in digestive surgery". Ann Surg 244 (5): 668–76. doi:10.1097/01.sla.0000225356.04304.bc. PMC 1856609. PMID 17060757. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1856609.
- ^ a b Stolberg HO, Norman G, Trop I (2004). "Randomized controlled trials". Am J Roentgenol 183 (6): 1539–44. PMID 15547188. http://www.ajronline.org/cgi/content/full/183/6/1539.
- ^ Meldrum ML (2000). "A brief history of the randomized controlled trial. From oranges and lemons to the gold standard". Hematol Oncol Clin North Am 14 (4): 745–60, vii. doi:10.1016/S0889-8588(05)70309-9. PMID 10949771.
- ^ Freedman B (1987). "Equipoise and the ethics of clinical research". N Engl J Med 317 (3): 141–5. doi:10.1056/NEJM198707163170304. PMID 3600702.
- ^ Gifford F (1995). "Community-equipoise and the ethics of randomized clinical trials". Bioethics 9 (2): 127–48. doi:10.1111/j.1467-8519.1995.tb00306.x. PMID 11653056.
- ^ Edwards SJL, Lilford RJ, Hewison J (1998). "The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals". Br Med J 317 (7167): 1209–12. PMC 1114158. PMID 9794861. http://www.bmj.com/cgi/content/full/317/7167/1209.
- ^ Zelen M (1979). "A new design for randomized clinical trials". N Engl J Med 300 (22): 1242–5. doi:10.1056/NEJM197905313002203. PMID 431682. http://content.nejm.org/cgi/content/abstract/300/22/1242.
- ^ Torgerson DJ, Roland M (1998). "What is Zelen's design?". Br Med J 316 (7131): 606. PMC 1112637. PMID 9518917. http://www.bmj.com/cgi/content/full/316/7131/606.
- ^ a b Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG (2010). "The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed". BMJ 340: c723. doi:10.1136/bmj.c723. PMC 2844941. PMID 20332510. http://www.bmj.com/cgi/content/full/340/mar23_1/c723.
- ^ Jones, Byron; Kenward, Michael G. (2003). Design and Analysis of Cross-Over Trials (Second ed.). London: Chapman and Hall.
- ^ Vonesh, Edward F.; Chinchilli, Vernon G. (1997). "Crossover Experiments". Linear and Nonlinear Models for the Analysis of Repeated Measurements. London: Chapman and Hall. pp. 111–202.
- ^ a b c d Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group (2008). "Improving the reporting of pragmatic trials: an extension of the CONSORT statement". BMJ 337: a2390. doi:10.1136/bmj.a2390. PMID 19001484. http://www.bmj.com/cgi/content/full/337/nov11_2/a2390.
- ^ a b c d Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group (2006). "Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement". JAMA 295 (10): 1152–60. doi:10.1001/jama.295.10.1152. PMID 16522836. http://jama.ama-assn.org/cgi/content/full/295/10/1152.
- ^ a b c d e f g h i j k Schulz KF, Grimes DA (2002). "Generation of allocation sequences in randomised trials: chance, not choice". Lancet 359 (9305): 515–9. doi:10.1016/S0140-6736(02)07683-3. PMID 11853818. http://www.who.int/entity/rhl/LANCET_515-519.pdf.
- ^ a b Lachin JM (1988). "Statistical properties of randomization in clinical trials". Control Clin Trials 9 (4): 289–311. doi:10.1016/0197-2456(88)90045-1. PMID 3060315.
- ^ Buyse ME (1989). "Analysis of clinical trial outcomes: some comments on subgroup analyses". Control Clin Trials 10 (4 Suppl): 187S–194S. doi:10.1016/0197-2456(89)90057-3. PMID 2605967.
- ^ a b c d e f Lachin JM, Matts JP, Wei LJ (1988). "Randomization in clinical trials: conclusions and recommendations". Control Clin Trials 9 (4): 365–74. doi:10.1016/0197-2456(88)90049-9. PMID 3203526.
- ^ Rosenberger WF, Lachin JM (1993). "The use of response-adaptive designs in clinical trials". Control Clin Trials 14 (6): 471–84. doi:10.1016/0197-2456(93)90028-C. PMID 8119063.
- ^ Forder PM, Gebski VJ, Keech AC (2005). "Allocation concealment and blinding: when ignorance is bliss". Med J Aust 182 (2): 87–9. PMID 15651970. http://www.mja.com.au/public/issues/182_02_170105/for10877_fm.html.
- ^ Pildal J, Chan AW, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC (2005). "Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study". BMJ 330 (7499): 1049. doi:10.1136/bmj.38414.422650.8F. PMC 557221. PMID 15817527. http://www.bmj.com/cgi/content/full/330/7499/1049.
- ^ a b c Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA (2008). "Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study". BMJ 336 (7644): 601–5. doi:10.1136/bmj.39465.451748.AD. PMC 2267990. PMID 18316340. http://www.bmj.com/cgi/content/full/336/7644/601.
- ^ Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, Bhandari M, Guyatt GH (2001). "Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials". J Am Med Assoc 285 (15): 2000–3. doi:10.1001/jama.285.15.2000. PMID 11308438. http://jama.ama-assn.org/cgi/content/full/285/15/2000.
- ^ Haahr MT, Hróbjartsson A (2006). "Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors". Clin Trials 3 (4): 360–5. doi:10.1177/1740774506069153. PMID 17060210. http://ctj.sagepub.com/cgi/content/abstract/3/4/360.
- ^ Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al (2007). "The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial". Lancet 369 (9566): 1016–26. doi:10.1016/S0140-6736(07)60461-9. PMC 2039891. PMID 17382828. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2039891.
- ^ Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J (1995). "Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial". BMJ 310 (6991): 1360–2. PMC 2549744. PMID 7787537. http://www.bmj.com/cgi/content/full/310/6991/1360.
- ^ Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M; Japan Gast Study Group (2008). "Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial". Lancet 372 (9636): 392–7. doi:10.1016/S0140-6736(08)61159-9. PMID 18675689.
- ^ Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R (1994). "The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial". Neurology 44 (1): 16–20. PMID 8290055. http://www.neurology.org/cgi/content/abstract/44/1/16.
- ^ Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001). "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial". Lancet 358 (9286): 958–65. doi:10.1016/S0140-6736(01)06102-5. PMID 11583749.
- ^ Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001). "Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial". J Am Med Assoc 285 (13): 1711–8. doi:10.1001/jama.285.13.1711. PMID 11277825. http://jama.ama-assn.org/cgi/content/full/285/13/1711.
- ^ a b Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators (2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial". J Am Med Assoc 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397. http://jama.ama-assn.org/cgi/content/full/288/3/321.
- ^ Hollis S, Campbell F (1999). "What is meant by intention to treat analysis? Survey of published randomised controlled trials". Br Med J 319 (7211): 670–4. PMC 28218. PMID 10480822. http://www.bmj.com/cgi/content/full/319/7211/670.
- ^ CONSORT Group. "Welcome to the CONSORT statement Website". http://www.consort-statement.org. Retrieved 2010-03-29.
- ^ National Health and Medical Research Council (1998-11-16). A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: Commonwealth of Australia. p. 56. ISBN 1864960485. http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/cp30.pdf. Retrieved 2010-03-28.
- ^ a b Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D; Methods Work Group, Third US Preventive Services Task Force (2001). "Current methods of the US Preventive Services Task Force: a review of the process". Am J Prev Med 20 (3 Suppl): 21–35. doi:10.1016/S0749-3797(01)00261-6. PMID 11306229. http://www.ahrq.gov/clinic/ajpmsuppl/review.pdf.
- ^ Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ; GRADE Working Group (2008). "What is "quality of evidence" and why is it important to clinicians?". BMJ 336 (7651): 995–8. doi:10.1136/bmj.39490.551019.BE. PMC 2364804. PMID 18456631. http://www.bmj.com/cgi/content/full/336/7651/995.
- ^ Oxford Centre for Evidence-based Medicine (2009 March). "Levels of evidence". http://www.cebm.net/index.aspx?o=1025. Retrieved 2010-03-28.
- ^ a b c Anderson JL, Pratt CM, Waldo AL, Karagounis LA (1997). "Impact of the Food and Drug Administration approval of flecainide and encainide on coronary artery disease mortality: putting "Deadly Medicine" to the test". Am J Cardiol 79 (1): 43–7. doi:10.1016/S0002-9149(96)00673-X. PMID 9024734. http://www.ajconline.org/article/S0002-9149%2896%2900673-X/abstract.
- ^ a b Rubin R (2006-10-16). "In medicine, evidence can be confusing - deluged with studies, doctors try to sort out what works, what doesn't". USA Today. http://www.usatoday.com/news/health/2006-10-15-medical-evidence-cover_x.htm. Retrieved 2010-03-22.
- ^ "Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators". N Engl J Med 321 (6): 406–12. 1989. doi:10.1056/NEJM198908103210629. PMID 2473403. http://content.nejm.org/cgi/content/abstract/321/6/406.
- ^ Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al (2004). "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial". JAMA 291 (14): 1701–12. doi:10.1001/jama.291.14.1701. PMID 15082697. http://jama.ama-assn.org/cgi/content/full/291/14/1701.
- ^ Grodstein F, Clarkson TB, Manson JE (2003). "Understanding the divergent data on postmenopausal hormone therapy". N Engl J Med 348 (7): 645–50. doi:10.1056/NEJMsb022365. PMID 12584376. http://content.nejm.org/cgi/content/extract/348/7/645.
- ^ Vandenbroucke JP (2009). "The HRT controversy: observational studies and RCTs fall in line". Lancet 373 (9671): 1233–5. doi:10.1016/S0140-6736(09)60708-X. PMID 19362661. http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(09)60708-X.
- ^ Hsu A, Card A, Lin SX, Mota S, Carrasquillo O, Moran A (2009). "Changes in postmenopausal hormone replacement therapy use among women with high cardiovascular risk". Am J Public Health 99 (12): 2184–7. doi:10.2105/AJPH.2009.159889. PMID 19833984. http://ajph.aphapublications.org/cgi/content/full/99/12/2184.
- ^ a b c d e Black N (1996). "Why we need observational studies to evaluate the effectiveness of health care". BMJ 312 (7040): 1215–8. PMC 2350940. PMID 8634569. http://www.bmj.com/cgi/content/full/bmj%3B312/7040/1215.
- ^ a b c Sanson-Fisher RW, Bonevski B, Green LW, D'Este C (2007). "Limitations of the randomized controlled trial in evaluating population-based health interventions". Am J Prev Med 33 (2): 155–61. doi:10.1016/j.amepre.2007.04.007. PMID 17673104. http://www.ajpm-online.net/article/S0749-3797%2807%2900225-5/abstract.
- ^ a b Rothwell PM (2005). "External validity of randomised controlled trials: "to whom do the results of this trial apply?"". Lancet 365 (9453): 82–93. doi:10.1016/S0140-6736(04)17670-8. PMID 15639683. http://apps.who.int/rhl/Lancet_365-9453.pdf.
- ^ Van Spall HG, Toren A, Kiss A, Fowler RA (2007). "Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review". JAMA 297 (11): 1233–40. doi:10.1001/jama.297.11.1233. PMID 17374817. http://jama.ama-assn.org/cgi/content/full/297/11/1233.
- ^ a b Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS (2006). "Effect of a US National Institutes of Health programme of clinical trials on public health and costs". Lancet 367 (9519): 1319–27. doi:10.1016/S0140-6736(06)68578-4. PMID 16631910. http://www.chrp.org/pdf/HSR20070511.pdf.
- ^ a b Yitschaky O, Yitschaky M, Zadik Y (May 2011). "Case report on trial: Do you, Doctor, swear to tell the truth, the whole truth and nothing but the truth?" (PDF). J Med Case Reports 5 (1): 179. PMID 21569508. http://www.jmedicalcasereports.com/content/pdf/1752-1947-5-179.pdf.
- ^ a b Benson K, Hartz AJ (2000). "A comparison of observational studies and randomized, controlled trials". N Engl J Med 342 (25): 1878–86. doi:10.1056/NEJM200006223422506. PMID 10861324. http://content.nejm.org/cgi/content/full/342/25/1878.
- ^ a b Concato J, Shah N, Horwitz RI (2000). "Randomized, controlled trials, observational studies, and the hierarchy of research designs". N Engl J Med 342 (25): 1887–92. doi:10.1056/NEJM200006223422507. PMC 1557642. PMID 10861325. http://nejm.highwire.org/cgi/content/full/342/25/1887.
- ^ Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J (2001). "Comparison of evidence of treatment effects in randomized and nonrandomized studies". J Am Med Assoc 286 (7): 821–30. doi:10.1001/jama.286.7.821. PMID 11497536. http://jama.ama-assn.org/cgi/content/full/286/7/821.
- ^ Vandenbroucke JP (2008). "Observational research, randomised trials, and two views of medical science". PLoS Med 5 (3): e67. doi:10.1371/journal.pmed.0050067. PMC 2265762. PMID 18336067. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2265762.
- ^ a b Glasziou P, Chalmers I, Rawlins M, McCulloch P (2007). "When are randomised trials unnecessary? Picking signal from noise". Br Med J 334 (7589): 349–51. doi:10.1136/bmj.39070.527986.68. PMC 1800999. PMID 17303884. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1800999.
- ^ Einhorn LH (2002). "Curing metastatic testicular cancer". Proc Natl Acad Sci U S A 99 (7): 4592–5. doi:10.1073/pnas.072067999. PMC 123692. PMID 11904381. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=123692.
- ^ Bekelman JE, Li Y, Gross CP (2003). "Scope and impact of financial conflicts of interest in biomedical research: a systematic review". J Am Med Assoc 289 (4): 454–65. doi:10.1001/jama.289.4.454. PMID 12533125. http://jama.ama-assn.org/cgi/content/full/289/4/454.
- ^ a b Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, Sprague S, Mears D, Schemitsch EH, Heels-Ansdell D, Devereaux PJ (2004). "Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials". Can Med Assoc J 170 (4): 477–80. PMC 332713. PMID 14970094. http://ecmaj.com/cgi/content/full/170/4/477.
- ^ Appelbaum PS, Roth LH, Lidz C (1982). "The therapeutic misconception: informed consent in psychiatric research". Int J Law Psychiatry 5 (3–4): 319–29. doi:10.1016/0160-2527(82)90026-7. PMID 6135666.
- ^ a b Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, Kass N, King NM, Lidz CW, Miller FG, Nelson DK, Peppercorn J, Rothschild BB, Sankar P, Wilfond BS, Zimmer CR (2007). "Clinical trials and medical care: defining the therapeutic misconception". PLoS Med 4 (11): e324. doi:10.1371/journal.pmed.0040324. PMC 2082641. PMID 18044980. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2082641.
- ^ Wittes J (2002). "Sample size calculations for randomized controlled trials". Epidemiol Rev 24 (1): 39–53. doi:10.1093/epirev/24.1.39. PMID 12119854.
- ^ Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR (1978). "The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials". N Engl J Med 299 (13): 690–4. doi:10.1056/NEJM197809282991304. PMID 355881. http://content.nejm.org/cgi/content/abstract/299/13/690.
- ^ Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P (2009-05-12). "Reporting of sample size calculation in randomised controlled trials: review". Br Med J 338: b1732. doi:10.1136/bmj.b1732. PMC 2680945. PMID 19435763. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2680945.
- ^ Jain SL (2010). "The mortality effect: counting the dead in the cancer trial". Public Culture 21 (1): 89–117. doi:10.1215/08992363-2009-017.
- ^ "How Well Do Meta-Analyses Disclose Conflicts of Interests in Underlying Research Studies | The Cochrane Collaboration". Cochrane.org. http://www.cochrane.org/news/blog/how-well-do-meta-analyses-disclose-conflicts-interests-underlying-research-studies. Retrieved 2011-08-19.
- ^ a b Farrington DP, Welsh BC (2005). "Randomized experiments in criminology: What have we learned in the last two decades?". Journal of Experimental Criminology 1 (1): 9–38. doi:10.1007/s11292-004-6460-0.
- ^ Hollin CR (2008). "Evaluating offending behaviour programmes: does only randomization glister?". Criminology and Criminal Justice 8 (1): 89–106. doi:10.1177/1748895807085871.
- ^ Walker HM, Seeley JR, Small J, Severson HH, Graham BA, Feil EG, Serna L, Golly AM, Forness SR (2009). "A randomized controlled trial of the First Step to Success early intervention. Demonstration of program efficacy outcomes in a diverse, urban school district". Journal of Emotional and Behavioral Disorders 17 (4): 197–212. doi:10.1177/1063426609341645.
- ^ Bradshaw CP, Zmuda JH, Kellam SG, Ialongo NS (2009). "Longitudinal impact of two universal preventive interventions in first grade on educational outcomes in high school". Journal of Educational Psychology 101 (4): 926–937. doi:10.1037/a0016586.
- ^ Duflo E, Glennerster R, Kremer M (2006-12-12). "Using randomization in development economics research: a toolkit" (PDF). MIT Department of Economics. Archived from the original on 2007-01-19. http://web.archive.org/web/20070119193234/http://www.povertyactionlab.com/papers/Using+Randomization+in+Development+Economics.pdf. Working Paper No. 06-36
- ^ Banerjee AV, Cole S, Duflo E, Linden L (2007). "Remedying education: evidence from two randomized experiments in India". Quarterly Journal of Economics 122 (3): 1235–1264. doi:10.1162/qjec.122.3.1235.
- ^ Karlan D, Zinman J (2010). "Expanding credit access: using randomized supply decisions to estimate the impacts". Review of Financial Studies 23 (1): 433–464. doi:10.1093/rfs/hhp092.
- ^ a b Olken BA (2007). "Monitoring corruption: evidence from a field experiment in Indonesia". Journal of Political Economy 115 (2): 200–249. doi:10.1086/517935.
- Bhargava, Alok "Randomized controlled experiments in health and social sciences: Some conceptual issues". Economics and Human Biology, 2008, 6, 293-298.
- Domanski MJ, McKinlay S. Successful randomized trials: a handbook for the 21st century. Philadelphia: Lippincott Williams & Wilkins, 2009. ISBN 978-0-7817-7945-6.
- Jadad AR, Enkin M. Randomized controlled trials: questions, answers, and musings. 2nd ed. Malden, Mass.: Blackwell, 2007. ISBN 978-1-4051-3266-4.
- Matthews JNS. Introduction to randomized controlled clinical trials. 2nd ed. Boca Raton, Fla.: CRC Press, 2006. ISBN 1-58488-624-2.
- Nezu AM, Nezu CM. Evidence-based outcome research: a practical guide to conducting randomized controlled trials for psychosocial interventions. Oxford: Oxford University Press, 2008. ISBN 978-0-19-530463-3.
- Solomon PL, Cavanaugh MM, Draine J. Randomized controlled trials: design and implementation for community-based psychosocial interventions. New York: Oxford University Press, 2009. ISBN 978-0-19-533319-0.
- Torgerson DJ, Torgerson C. Designing randomised trials in health, education and the social sciences: an introduction. Basingstoke, England, and New York: Palgrave Macmillan, 2008. ISBN 978-0-230-53735-4.
- Bland M. Directory of randomisation software and services. University of York, 2008 March 19.
- Evans I, Thornton H, Chalmers I. Testing treatments: better research for better health care. London: Pinter & Martin, 2010. ISBN 978-1-905177-35-6.
- Gelband H. The impact of randomized clinical trials on health policy and medical practice: background paper. Washington, DC: U.S. Congress, Office of Technology Assessment, 1983. (Report OTA-BP-H-22.)
- REFLECT (Reporting guidElines For randomized controLled trials for livEstoCk and food safeTy) Statement
- Wathen JK, Cook JD. Power and bias in adaptively randomized clinical trials. M. D. Anderson Cancer Center, University of Texas, 2006 July 12.
Biomedical research: Clinical study design / Design of experiments Overview Controlled study
(EBM I to II-1; A to B)
(EBM II-2 to II-3; B to C)
occurrence: Incidence (Cumulative incidence) · Prevalence (Point prevalence, Period prevalence)
association: absolute (Absolute risk reduction, Attributable risk, Attributable risk percent) · relative (Relative risk, Odds ratio, Hazard ratio)
other: Virulence · Infectivity · Mortality rate · Morbidity · Case fatality · Specificity and sensitivity · Likelihood-ratios · Pre/post-test probability
Trial/test types Analysis of clinical trials
Interpretation of results Design of experiments Scientific
RandomizedBlock · Generalized randomized block design (GRBD) · Latin square · Graeco-Latin square · Hyper-Graeco-Latin square · Latin hypercube
Repeated measures design · Crossover study ·
Randomized controlled trial · Sequential analysis · Sequential probability ratio test
Statistics Descriptive statisticsSummary tables Data collectionDesigning studiesUncontrolled studies Statistical inferenceFrequentist inferenceSpecific tests Correlation and regression analysisNon-standard predictorsPartition of variance Categorical, multivariate, time-series, or survival analysis Applications
Wikimedia Foundation. 2010.
Look at other dictionaries:
randomized controlled trial — klinikinis atsitiktinių imčių tyrimas statusas T sritis biomedicinos mokslai apibrėžtis ↑Eksperimentinis tyrimas, kai poveikio bei ↑kontrolinės grupės sudaromos iš ↑populiacijos atsitiktinumo principu pagrįstais metodais, o poveikis vertinamas… … Lithuanian dictionary (lietuvių žodynas)
Randomized Controlled Trial — Die randomisierte kontrollierte Studie (RCT englisch: randomized controlled trial) ist in der medizinischen Forschung das nachgewiesen beste Studiendesign, um bei einer eindeutigen Fragestellung eine eindeutige Aussage zu erhalten und die… … Deutsch Wikipedia
randomized controlled trial — ran·dom·ized controlled trial ran də .mīzd n a clinical trial in which the subjects are randomly distributed into groups which are either subjected to the experimental procedure (as use of a drug) or which serve as controls called also randomized … Medical dictionary
randomized controlled trial — see intervention study … Medical dictionary
randomized controlled trial — see intervention study … The new mediacal dictionary
Обследование Контрольное Случайное (Randomized Controlled Trial) — см. Изучение интервенционное. Источник: Медицинский словарь … Медицинские термины
randomized clinical trial — klinikinis atsitiktinių imčių tyrimas statusas T sritis biomedicinos mokslai apibrėžtis ↑Eksperimentinis tyrimas, kai poveikio bei ↑kontrolinės grupės sudaromos iš ↑populiacijos atsitiktinumo principu pagrįstais metodais, o poveikis vertinamas… … Lithuanian dictionary (lietuvių žodynas)
Cluster randomised controlled trial — A cluster randomised controlled trial is a type of randomised controlled trial in which groups of subjects (as opposed to individual subjects) are randomised. Cluster randomised controlled trials are also known as cluster randomised trials … Wikipedia
Controlled Substances Act — Acronym CSA Enacted by the 91st United States Congress Effective October 27, 1970 Citations Public La … Wikipedia
Randomized block design — In the statistical theory of the design of experiments, blocking is the arranging of experimental units in groups (blocks) that are similar to one another. Typically, a blocking factor is a source of variability that is not of primary interest to … Wikipedia